South Korea's SK Bioscience has begun R&D of a platform technology that could rapidly develop vaccines against mutated viruses, such as the new coronavirus and those causing MERS (Middle East respiratory syndrome) and SARS (severe acute respiratory syndrome), and help to more quickly deal with massive outbreaks of such emerging infectious diseases.
The new platform aims to provide the versatility to expedite vaccine development through an identical process, even for new mutated viruses causing respiratory diseases, and with strong safety despite high...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?